How McKesson's (MCK) Spotlight on Cell and Gene Therapies Has Changed Its Investment Story

• McKesson Corporation recently presented at the Cell & Gene Meeting on the Mesa in Phoenix, Arizona on October 6, 2025, with Joe DePinto highlighting the company's advancements in cell, gene, and advanced therapies.
• This event signals McKesson's continued emphasis on specialty pharmaceutical segments, which is drawing increased interest from both analysts and investors due to the ongoing shift towards higher-margin healthcare services.
• We'll explore how McKesson's intensified focus on specialty therapies and portfolio realignment could influence its investment outlook and long-term growth potential.

Find companies with promising cash flow potential yet trading below their fair value.

McKesson Investment Narrative Recap

Shareholders in McKesson need confidence in the company's strategy to pivot toward specialty pharmaceutical services and advanced therapies, positioning itself to benefit from higher-margin healthcare segments. The company's recent presentation at the Cell & Gene Meeting on the Mesa reinforces this narrative but does not materially change the immediate catalyst, which remains continued momentum in specialty revenue growth, nor does it diminish the key risk of pressure from drug pricing policies or industry consolidation. Of McKesson's recent announcements, its decision to separate the Medical-Surgical business stands out as most relevant, aiming to further concentrate resources on pharmaceuticals, oncology, and biopharma solutions, directly aligned with the expanding specialty segment that underpins current growth catalysts. However, investors should also be aware that, despite this focus, persistent regulatory changes and evolving competitive threats could...

Read the full narrative on McKesson (it's free!)

McKesson's outlook anticipates $478.8 billion in revenue and $5.3 billion in earnings by 2028. This is based on an expected annual revenue growth rate of 8.2% and a $2.1 billion increase in earnings from the current $3.2 billion.

Uncover how McKesson's forecasts yield a $829.57 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members offered five different fair value estimates for McKesson ranging from US$625 to US$999, with the highest views more than 50 percent above the lowest. While many are drawn to the growing specialty and oncology segment, you can see market participants weigh these opportunities against ongoing margin pressures and regulatory risk, explore how your outlook compares to these viewpoints.

Explore 5 other fair value estimates on McKesson - why the stock might be worth as much as 31% more than the current price!

Build Your Own McKesson Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your McKesson research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free McKesson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate McKesson's overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com